Avastin Not Good for Breast Cancer, FDA Panel Says

GAITHERSBURG, Md. -- An advisory panel has voted 12 to 1 to recommend that the U.S. Food and Drug Administration revoke their approval of the blockbuster cancer drug Avastin -- known generically as bevacizumab -- for the treatment of advanced breast cancer. The decision follows the results of two large clinical trials which failed to demonstrate a clinically meaningful benefit of the drug, which carries serious side effects. The Oncologic Drugs Advisory Committee voted that Avastin -- when...Full Story
Commenting on this article is closed.